ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1884

Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
Abstract Number: 1885

Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial
Abstract Number: 1886

Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH
Abstract Number: 1887

Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
Abstract Number: 1888

Successful Evaluation of Spinal Mobility Measurements with the Epionics SPINE Device in Patients with Axial Spondyloarthritis Compared to Controls
Abstract Number: 1889

Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Abstract Number: 1890

Daily Management of Patients with Axial Spondyloarthritis: Self-monitoring of Disease Activity with a Smartphone App Is Feasible – a Proof of Concept Study
Abstract Number: 1891

Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Abstract Number: 1892

Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Abstract Number: 1893

Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Abstract Number: 1894

Use of Facebook and Electronic Patient Portal to Identify Axial Spondyloarthritis in Patients with Chronic Back Pain
Abstract Number: 1895

Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Abstract Number: 1896

No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 1897

Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
Abstract Number: 1898

Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].